VENTOLIN ROTACAPS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VENTOLIN ROTACAPS (VENTOLIN ROTACAPS).
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
| Metabolism | Metabolized primarily by sulfation in the gut wall and to a lesser extent by hepatic conjugation via monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). |
| Excretion | Renal (60-70% as unchanged drug and metabolites, primarily as sulfate conjugate); biliary/fecal (minimal, <10%) |
| Half-life | Terminal elimination half-life: 3-6 hours in adults; prolonged in patients with renal impairment or hepatic dysfunction (up to 12 hours). Clinical context: Dosing interval typically every 4-6 hours. |
| Protein binding | Approximately 10% bound to plasma proteins (albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Approximately 2-3 L/kg; indicates extensive distribution into tissues (e.g., lungs, skeletal muscle). |
| Bioavailability | Inhalation: 10-20% (varies with device and technique). Oral: 30-50% (first-pass metabolism produces sulfate conjugate; low systemic bioavailability). |
| Onset of Action | Inhalation: 5-15 minutes; peak effect at 30-60 minutes. Oral: 30-90 minutes. |
| Duration of Action | Inhalation: 4-6 hours (bronchodilation). Clinical note: Tolerance may develop with chronic use; duration may be shorter in acute severe asthma. |
Inhalation via Rotahaler: 200-400 mcg (1-2 capsules) every 4-6 hours as needed for bronchospasm; maximum 4 times daily.
| Dosage form | CAPSULE |
| Renal impairment | No dosage adjustment necessary for renal impairment. |
| Liver impairment | No dosage adjustment necessary for hepatic impairment. |
| Pediatric use | Children 4-11 years: 200 mcg (1 capsule) via Rotahaler every 4-6 hours as needed; maximum 4 times daily. Children over 12 years: same as adult. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential for increased sensitivity and tremor. Monitor cardiovascular effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VENTOLIN ROTACAPS (VENTOLIN ROTACAPS).
| Breastfeeding | Excreted in human breast milk; estimated infant dose <2% of maternal weight-adjusted dose. M/P ratio not established. Use with caution, especially in preterm infants due to potential irritation and cardiovascular effects. Consider alternative if infant shows signs of beta-agonist stimulation. |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in pregnant women; animal studies show adverse effects at high doses. In first trimester, use only if benefit justifies risk. Second and third trimesters: risk of fetal tachycardia, hypoglycemia, and maternal pulmonary edema if used with beta-agonists. Avoid for tocolysis due to serious maternal adverse events (pulmonary edema, death). |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to albuterol or any component"]
| Precautions | ["Paradoxical bronchospasm may occur","Cardiovascular effects: increases heart rate, blood pressure","Hypokalemia may occur","Risk of immediate hypersensitivity reactions","Do not use as substitute for inhaled or oral corticosteroids"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, serum potassium (risk of hypokalemia), and respiratory status. Fetal monitoring for heart rate changes (tachycardia, arrhythmias) and signs of distress. Assess uterine activity if used for tocolysis. Monitor for signs of pulmonary edema if used with other beta-agonists. |
| Fertility Effects | No known adverse effects on fertility in humans. Animal studies show no impairment of fertility at therapeutic doses. |